Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025
Nyxoah (Euronext Brussels/Nasdaq: NYXH), a company developing breakthrough neuromodulation treatments for Obstructive Sleep Apnea (OSA), has scheduled the release of its fourth quarter and financial year 2024 results on March 13, 2025.
The company will host a conference call with management to discuss the financial results on the same day at 1:00pm CET / 8:00am ET. Investors can access the webcast through the company's Investor Relations page or participate in the Q&A session by registering for the earnings call at least 10 minutes before the start time.
Nyxoah (Euronext Bruxelles/Nasdaq: NYXH), un'azienda che sviluppa trattamenti innovativi di neuromodulazione per l'Apnea Ostruttiva del Sonno (OSA), ha programmato la pubblicazione dei risultati del quarto trimestre e dell'anno finanziario 2024 per il 13 marzo 2025.
L'azienda organizzerà una teleconferenza con il management per discutere i risultati finanziari lo stesso giorno alle 13:00 CET / 8:00 ET. Gli investitori possono accedere al webcast tramite la pagina delle Relazioni con gli Investitori dell'azienda o partecipare alla sessione di domande e risposte registrandosi per la teleconferenza sugli utili almeno 10 minuti prima dell'orario di inizio.
Nyxoah (Euronext Bruselas/Nasdaq: NYXH), una empresa que desarrolla tratamientos innovadores de neuromodulación para la Apnea Obstructiva del Sueño (OSA), ha programado la publicación de sus resultados del cuarto trimestre y del año fiscal 2024 para el 13 de marzo de 2025.
La empresa llevará a cabo una conferencia telefónica con la dirección para discutir los resultados financieros el mismo día a las 1:00 p.m. CET / 8:00 a.m. ET. Los inversores pueden acceder a la transmisión a través de la página de Relaciones con Inversores de la empresa o participar en la sesión de preguntas y respuestas registrándose para la llamada de ganancias al menos 10 minutos antes de la hora de inicio.
Nyxoah (유로넥스트 브뤼셀/나스닥: NYXH)는 폐쇄성 수면 무호흡증(OSA)을 위한 혁신적인 신경조절 치료법을 개발하는 회사로, 2024년 4분기 및 회계연도 실적 발표를 2025년 3월 13일로 예정하고 있습니다.
회사는 같은 날 CET 오후 1시 / ET 오전 8시에 재무 결과에 대해 논의하기 위해 경영진과 함께 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 회사의 투자자 관계 페이지를 통해 웹캐스트에 접근하거나, 수익 통화에 참여하기 위해 시작 시간보다 최소 10분 전에 등록하여 질문 및 답변 세션에 참여할 수 있습니다.
Nyxoah (Euronext Bruxelles/Nasdaq: NYXH), une entreprise développant des traitements novateurs de neuromodulation pour l'Apnée Obstructive du Sommeil (OSA), a prévu la publication de ses résultats du quatrième trimestre et de l'année financière 2024 pour le 13 mars 2025.
L'entreprise organisera une conférence téléphonique avec la direction pour discuter des résultats financiers le même jour à 13h00 CET / 8h00 ET. Les investisseurs peuvent accéder au webcast via la page des Relations Investisseurs de l'entreprise ou participer à la session de questions-réponses en s'inscrivant à l'appel de résultats au moins 10 minutes avant l'heure de début.
Nyxoah (Euronext Brüssel/Nasdaq: NYXH), ein Unternehmen, das bahnbrechende Neuromodulationstherapien für obstruktive Schlafapnoe (OSA) entwickelt, hat die Veröffentlichung seiner Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 für den 13. März 2025 angesetzt.
Das Unternehmen wird am selben Tag um 13:00 Uhr MEZ / 8:00 Uhr EST eine Telefonkonferenz mit dem Management abhalten, um die finanziellen Ergebnisse zu besprechen. Investoren können über die Investor-Relations-Seite des Unternehmens auf das Webcast zugreifen oder an der Q&A-Session teilnehmen, indem sie sich mindestens 10 Minuten vor Beginn der Gewinnanruf registrieren.
- None.
- None.
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025
Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and financial year 2024 on Thursday, March 13, 2025. Company management will host a conference call to discuss financial results that day beginning 1:00pm CET / 8:00am ET.
A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 and FY 2024 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.
If you plan to ask a question, please use the following link: Nyxoah's Q4 and FY 2024 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
The archived webcast will be available for replay shortly after the close of the call.
About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; receipt of FDA approval; entrance to the U.S. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward- looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
John Landry, Chief Financial Officer
IR@nyxoah.com
For Media
In United States
FINN Partners – Fern Lazar
fern.lazar@finnpartners.com
In Belgium/France
Backstage Communication – Gunther De Backer gunther@backstagecom.be
In International/Germany
MC Services – Anne Hennecke nyxoah@mc-services.eu
Attachment
FAQ
When will Nyxoah (NYXH) release its Q4 and FY 2024 earnings?
What time is Nyxoah's Q4 2024 earnings conference call?
How can investors access Nyxoah's Q4 2024 earnings call?
What is Nyxoah's (NYXH) main business focus?
